Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...
In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...
CrowdStrike's 2025 data shows attackers breach AI systems in 51 seconds. Field CISOs reveal how inference security platforms ...
The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...
Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock sinks as market gains: What you should know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.
Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...
CloseMate today opened early access for the world's first Fully Autonomous CRM powered by AGI-grade logic, introducing a shift from Software as a Service to Service as Software, a paradigm where you ...
Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...
The reported valuation aligns with where Manus had been headed before Meta intervened. The company had been raising new funds ...
Regionally adaptive governance, essential in the Indian context, remains inconsistent, with significant disparities between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback